Resistance profiles of cyclic and linear inhibitors of HIV-1 protease (Q44103468)

29 November 2017

title

Resistance profiles of cyclic and linear inhibitors of HIV-1 protease (English)

1 reference

29 November 2017

G Ahlsén

1

1 reference

29 November 2017

J Hultén

2

1 reference

29 November 2017

C F Shuman

3

1 reference

29 November 2017

A Poliakov

4

1 reference

29 November 2017

M T Lindgren

5

1 reference

29 November 2017

M Alterman

6

1 reference

29 November 2017

B Samuelsson

7

1 reference

29 November 2017

A Hallberg

8

1 reference

29 November 2017

U H Danielson

9

1 reference

29 November 2017

publication date

1 January 2002

1 reference

Antiviral Chemistry & Chemotherapy

29 November 2017

published in

1 reference

29 November 2017

volume

13

1 reference

29 November 2017

issue

1

1 reference

29 November 2017

page(s)

27-37

1 reference

Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Structure of a G48H mutant of HIV-1 protease explains how glycine-48 replacements produce mutants resistant to inhibitor drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Inhibitors of the C(2)-symmetric HIV-1 protease: nonsymmetric binding of a symmetric cyclic sulfamide with ketoxime groups in the P2/P2' side chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Structural and kinetic analysis of drug resistant mutants of HIV-1 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Targeting the HIV-protease in AIDS therapy: a current clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

Inhibitors of HIV-1 protease: a major success of structure-assisted drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020201300103

10.1177/095632020201300103

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference